Latest news
{{'2025-08-20T13:31:00Z' | dateFormatFilter}}
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
{{'2025-08-15T21:23:39Z' | dateFormatFilter}}
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
{{'2025-08-06T05:30:41Z' | dateFormatFilter}}
Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
Stay informed
Stay informed
Be the first one to read our company announcements and press releases. Sign up to Novo Nordisk News.
